onc Videos

Videos

Fractionated Busulfan Treatment Reduced Toxicities Among Patients With AML and MDS

06/14/2023

Featuring Uday Popat, MD

Uday Popat, MD, presented data from a clinical trial that indicated the fractionation of busulfan reduced toxicities among patients with AML and MDS. This data was presented at the 2023 ASCO annual meeting.

Uday Popat, MD, presented data...

06/14/2023

Oncology

Videos

Evaluating BCL6-Positive and CD10-Positive Expression for Mantle Cell Lymphoma Treatment and Management

06/14/2023

Featuring Won Jin Jeon, MD

At the 2023 ASCO annual meeting, Won Jin Jeon, MD, presented data from a meta-analysis that explored the prognostic value of identifying BCL6 and CD10 variants in the treatment and management of mantle cell lymphoma.

At the 2023 ASCO annual meeting,...

06/14/2023

Oncology

Lars Henrik Jensen, MD, University Hospital of Southern Denmark

Videos

Neoadjuvant Chemotherapy for Locally Advanced Colorectal Cancer

06/14/2023

On site at ASCO 2023, Dr Lars Henrik Jensen shares results from the phase 3 NeoCol trial evaluating the addition of neoadjuvant chemotherapy to initial surgery for patients with locally advanced colon cancer.

On site at ASCO 2023, Dr Lars...

06/14/2023

Oncology

Videos

MonumenTAL-1 Study Identifies Impressive Responses to Talquetamab Among Patients With Heavily Pretreated R/R MM

06/13/2023

Featuring Carolina Schinke, MD

Featuring Carolina Schinke, MD ...

At the 2023 ASCO annual meeting, Carolina Schinke, MD, discussed updated results from the MonumenTAL-1 trial which indicated that patients with heavily pretreated R/R multiple myeloma had impressive responses to treatment with talquetamab.

At the 2023 ASCO annual meeting,...

06/13/2023

Oncology

Videos

Glofitamab Monotherapy for Patients With R/R Diffuse Large B-Cell Lymphoma

06/13/2023

Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.

Lorenzo Falchi, MD presents...

06/13/2023

Oncology

Michael Castro, MD, Beverly Hills Cancer Center

Videos

Effect of Proton Pump Inhibitor Use on Glioblastoma Survival Outcomes

06/13/2023

Michael Castro, MD, discusses the results of a retrospective study evaluating the effect proton pump inhibition use may have on survival outcomes of patients with glioblastoma.

Michael Castro, MD, discusses...

06/13/2023

Oncology

Videos

Teclistamab Demonstrates Safety, Efficacy for Patients With R/R Multiple Myeloma

06/12/2023

Niels W.C.J. van de Donk, MD, PhD, presents 2-year follow-up results from the MajesTEC-1 trial, which indicated that teclistamab demonstrated safety and efficacy among heavily pre-treated patients with R/R multiple myeloma.

Niels W.C.J. van de Donk, MD,...

06/12/2023

Oncology

Videos

Talquetamab Plus Daratumumab Yields Durable Responses for Patients With R/R Multiple Myeloma

06/12/2023

Bhagirathbhai R. Dholaria, MBBS, highlights findings from the TRiMM-2 trial, which demonstrated that the combination of talquetamab and daratumumab was safe and effective for patients with R/R multiple myeloma.

Bhagirathbhai R. Dholaria, MBBS,...

06/12/2023

Oncology

Dorota Goplen, MD, Haukeland University Hospital

Videos

Sequential Bortezomib Plus Temozolomide is Safe, Effective for Recurrent Glioblastoma

06/12/2023

Dorota Goplen, MD, Haukeland University Hospital, Bergen, Norway, discusses results from a phase 1b/2 BORTEM-17 study evaluating the efficacy of sequential treatment with bortezomib and temozolomide for patients with glioblastoma and...

Dorota Goplen, MD, Haukeland...

06/12/2023

Oncology

Jason Luke, MD, UPMC Hillman Cancer Center

Videos

Adjuvant Pembrolizumab for Stage IIB/IIC Melanoma

06/12/2023

At the 2023 ASCO Annual Meeting, Jason Luke, MD, shares results from the protocol-specified final distant metastasis-free survival analysis of KEYNOTE-716, evaluating adjuvant pembrolizumab among patients with stage IIIB and IIIC resected...

At the 2023 ASCO Annual Meeting,...

06/12/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology